Rockefeller Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History
Bought
Maintained
Sold
Other funds holding PPH
Rockefeller Capital Management's PPH Position: Q3 2026 in Review
Rockefeller Capital Management reduced its VanEck Pharmaceutical ETF (PPH) stake by 41% in Q3 2026, selling an estimated $40.5K and leaving 521 shares worth $57K. The position accounts for ﹤0.01% of the portfolio, ranked #3380.
Rockefeller Capital Management first reported a position in PPH in Q2 2022 and has held it in 8 quarters since. The position peaked at $443K in Q3 2025. 154 funds tracked by Wall St. Rank hold PPH as of Q3 2026.
- Rockefeller Capital Management held 521 shares of VanEck Pharmaceutical ETF worth $57K as of Q3 2026.
- Rockefeller Capital Management sold 363 VanEck Pharmaceutical ETF shares in Q3 2026, an estimated $40.5K.
- VanEck Pharmaceutical ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3380 holding.
- Rockefeller Capital Management first reported a position in VanEck Pharmaceutical ETF in Q2 2022 and has held it in 8 quarters since.
- Rockefeller Capital Management's VanEck Pharmaceutical ETF position peaked at $443K in Q3 2025.
- 154 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.